{"title":"NRAS （Q16R）突变的间变性甲状腺癌多转移患者经抗pd1 +抗ctla4免疫治疗后长期完全缓解","authors":"Dimitri Anzellini, Marco Loddo, Sergio Del Bianco","doi":"10.21873/anticanres.17740","DOIUrl":null,"url":null,"abstract":"<p><strong>Background/aim: </strong>Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy. Its prognosis is poor, particularly in patients with distant metastasis. Treatment of ATC Is mostly palliative. In this report, we present the case of a patient affected by NRAS Q16R mutated, polymetastatic and multi-treated ATC, who showed complete remission of the disease after the use of an anti-PD1 and anti-CTLA4 doublet.</p><p><strong>Case report: </strong>We present the clinical case of an 82-year-old patient affected by polymetastatic anaplastic thyroid carcinoma carrying NRAS (Q16R) mutation, treated with surgery, radiotherapy and chemotherapy. Complete and long-lasting disease response was induced to the patient after immunotherapy anti PD1 plus anti CTLA4 (pembrolizumab + ipilimumab).</p><p><strong>Conclusion: </strong>The combination of pembrolizumab plus ipilimumab may represent a therapeutic strategy in patients with NRAS (Q16R) mutated anaplastic thyroid cancer.</p>","PeriodicalId":8072,"journal":{"name":"Anticancer research","volume":"45 9","pages":"3809-3816"},"PeriodicalIF":1.7000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma.\",\"authors\":\"Dimitri Anzellini, Marco Loddo, Sergio Del Bianco\",\"doi\":\"10.21873/anticanres.17740\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background/aim: </strong>Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy. Its prognosis is poor, particularly in patients with distant metastasis. Treatment of ATC Is mostly palliative. In this report, we present the case of a patient affected by NRAS Q16R mutated, polymetastatic and multi-treated ATC, who showed complete remission of the disease after the use of an anti-PD1 and anti-CTLA4 doublet.</p><p><strong>Case report: </strong>We present the clinical case of an 82-year-old patient affected by polymetastatic anaplastic thyroid carcinoma carrying NRAS (Q16R) mutation, treated with surgery, radiotherapy and chemotherapy. Complete and long-lasting disease response was induced to the patient after immunotherapy anti PD1 plus anti CTLA4 (pembrolizumab + ipilimumab).</p><p><strong>Conclusion: </strong>The combination of pembrolizumab plus ipilimumab may represent a therapeutic strategy in patients with NRAS (Q16R) mutated anaplastic thyroid cancer.</p>\",\"PeriodicalId\":8072,\"journal\":{\"name\":\"Anticancer research\",\"volume\":\"45 9\",\"pages\":\"3809-3816\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2025-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Anticancer research\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21873/anticanres.17740\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"ONCOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Anticancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21873/anticanres.17740","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
Long-lasting Complete Remission Following Immunotherapy With Anti-PD1 Plus Anti-CTLA4 in a Polymetastatic Patient With NRAS (Q16R) Mutated Anaplastic Thyroid Carcinoma.
Background/aim: Anaplastic thyroid cancer (ATC) is a rare and aggressive malignancy. Its prognosis is poor, particularly in patients with distant metastasis. Treatment of ATC Is mostly palliative. In this report, we present the case of a patient affected by NRAS Q16R mutated, polymetastatic and multi-treated ATC, who showed complete remission of the disease after the use of an anti-PD1 and anti-CTLA4 doublet.
Case report: We present the clinical case of an 82-year-old patient affected by polymetastatic anaplastic thyroid carcinoma carrying NRAS (Q16R) mutation, treated with surgery, radiotherapy and chemotherapy. Complete and long-lasting disease response was induced to the patient after immunotherapy anti PD1 plus anti CTLA4 (pembrolizumab + ipilimumab).
Conclusion: The combination of pembrolizumab plus ipilimumab may represent a therapeutic strategy in patients with NRAS (Q16R) mutated anaplastic thyroid cancer.
期刊介绍：
ANTICANCER RESEARCH is an independent international peer-reviewed journal devoted to the rapid publication of high quality original articles and reviews on all aspects of experimental and clinical oncology. Prompt evaluation of all submitted articles in confidence and rapid publication within 1-2 months of acceptance are guaranteed.
ANTICANCER RESEARCH was established in 1981 and is published monthly (bimonthly until the end of 2008). Each annual volume contains twelve issues and index. Each issue may be divided into three parts (A: Reviews, B: Experimental studies, and C: Clinical and Epidemiological studies).
Special issues, presenting the proceedings of meetings or groups of papers on topics of significant progress, will also be included in each volume. There is no limitation to the number of pages per issue.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
